Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mode of Action Study of Vilaprisan vs Ulipristal in Uterine Fibroids
NCT03342859Phase 1Terminated
- Sponsor
- Bayer
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vilaprisan in Uterine Fibroids (UF) (3 arms), sponsored by Bayer. Primary endpoints: Expression level of Ki-67 in the endometrium up to 20 weeks, Expression level of Ki-67 in fibroid tissue up to 12 weeks and 3 more. Started Nov 2017; status: terminated.
02
Drugs
vilaprisan
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03342859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342859.